CClinicalTrials.gg
Sign In
RecruitingNCT07855965NEOCTATCUpdated Oct 2, 2026

Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer

A Phase 2 interventional study of Cryo-Thermal Ablation and Toripalimab in Carcinoma, Non-Small-Cell Lung (NSCLC), sponsored by West China Hospital. Recruiting at 9 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by West China Hospital · Phase 2, Interventional, and Treatment

Updated Oct 2, 2026Newly registeredGo to Updates ↓
Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Neoadjuvant chemoimmunotherapy has improved outcomes in patients with resectable non-small cell lung cancer (NSCLC), but a substantial proportion of patients do not achieve a major pathological response. Cryo-Thermal Ablation may induce immunogenic tumor cell death and remodel the tumor immune microenvironment, potentially enhancing the antitumor activity of subsequent chemoimmunotherapy.

This multicenter, single-arm, open-label, prospective Phase II study will evaluate the efficacy and safety of CT-guided Cryo-Thermal Ablation followed by toripalimab plus platinum-based doublet chemotherapy as neoadjuvant treatment for patients with resectable stage IB-IIIB NSCLC. For stage IB disease, only patients with cT2aN0M0 disease and a maximum primary tumor diameter of 4.0 cm are eligible. Patients with more advanced disease must be considered resectable by multidisciplinary team assessment according to the study protocol.

Approximately 40 participants will receive Cryo-Thermal Ablation followed by 3 planned cycles of toripalimab plus platinum-based doublet chemotherapy and subsequent curative-intent surgical resection.

The primary outcome is the pathological complete response (pCR) rate. Secondary outcomes include major pathological response (MPR) rate, objective response rate (ORR), R0 resection rate, event-free survival (EFS), overall survival (OS), treatment-emergent adverse events (TEAEs), and health-related quality of life.

Exploratory translational analyses will investigate treatment-associated local and systemic antitumor immune responses and molecular dynamics using spatial transcriptomics, T-cell receptor sequencing, tumor genomic profiling, circulating tumor DNA analysis, imaging mass cytometry, and exploratory intratumoral metagenomic and metabolomic profiling.

02

Conditions studied

  • Carcinoma, Non-Small-Cell Lung (NSCLC)

Keywords

  • Neoadjuvant therapy
  • Resectable non-small cell lung cancer
  • Ablation
  • Toripalimab
  • PD-1 inhibitor
  • Chemoimmunotherapy
03

In context

Carcinoma

6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.

This study's planned enrollment of 40 is below the median of 45 across 5,170 interventional studies indexed under Carcinoma.

Browse Carcinoma studies →

Lead sponsor

West China Hospital is the lead sponsor of 483 studies on the registry; 240 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Diagnosis, Stage, and Resectability

    • Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
    • Clinical stage IB-IIIB according to the 9th edition IASLC/AJCC TNM classification.
    • For stage IB disease, only patients with a maximum tumor diameter of 4.0 cm (cT2aN0M0) are eligible.
    • The disease must be considered resectable by multidisciplinary team (MDT) assessment with curative-intent surgery planned after neoadjuvant treatment.
    • The primary lung lesion must be technically amenable to percutaneous biopsy and CT-guided Cryo-Thermal Ablation..
    • No prior systemic or local anti-tumor therapy for the current NSCLC.

  2. Age, Performance Status, and General Condition

    • Age 18-80 years.
    • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
    • Estimated life expectancy >6 months.
    • Able to understand and voluntarily sign the informed consent form and willing to comply with study treatment, specimen collection, and follow-up requirements.

  3. Tumor Tissue and Pulmonary Function

    • Willing to provide tumor tissue and blood samples required by the study protocol.
    • Adequate pulmonary function for the planned treatment and subsequent pulmonary resection, including: FEV1 ≥1.2 L or ≥50% of predicted value; and predicted postoperative FEV1≥30% of predicted value.

  4. Adequate Organ Function

    Laboratory assessments performed within 7 days before the first study intervention must meet the following criteria:

    • Hemoglobin ≥9.0 g/dL;
    • absolute neutrophil count ≥1.0 × 10⁹/L;
    • platelet count ≥90 × 10⁹/L;
    • total bilirubin ≤2.0 × upper limit of normal (ULN);
    • alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤2.5 × ULN;
    • serum creatinine ≤2.0 mg/dL and creatinine clearance ≥60 mL/min;
    • adequate thyroid function. If thyroid-stimulating hormone (TSH) is outside the normal range, free T3 and free T4 must be within clinically acceptable limits; no clinically significant abnormality in cardiac enzyme testing;
    • international normalized ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5 × ULN, unless abnormalities are attributable to protocol-permitted anticoagulation.

  5. Reproductive Requirements

    • Female participants of childbearing potential must have a negative serum or urine human chorionic gonadotropin (HCG) pregnancy test within 7 days before initiation of study treatment.
    • Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception from enrollment until at least 180 days after the last dose of study systemic therapy.

Exclusion criteria

Exclusion Criteria

  1. Histological or Molecular Characteristics

    • Small-cell lung cancer (SCLC) or mixed histology containing a small-cell component.
    • Presence of protocol-defined actionable oncogenic alterations detected by tumor tissue and/or plasma-based molecular testing, including:
    • EGFR sensitizing or protocol-defined activating alterations, including exon 19 deletion, L858R, G719X, S768I, L861Q, or exon 20 insertion;
    • ALK rearrangement;
    • ROS1 rearrangement;
    • MET exon 14 skipping alteration or protocol-defined MET amplification;
    • KRAS G12C;
    • BRAF V600E;
    • NTRK1/2/3 fusion;
    • RET rearrangement; or HER2 alteration as defined in the study protocol.

  2. Contraindications to Percutaneous Biopsy or Cryo-Thermal Ablation

    • Active clinically significant hemoptysis, defined as ≥1/2 teaspoon of fresh blood, within 2 weeks before the planned procedure.
    • Clinically significant bleeding tendency or coagulation disorder that cannot be adequately corrected before biopsy or ablation.
    • Therapeutic anticoagulant or vitamin K antagonist treatment that cannot be safely interrupted or managed during the periprocedural period according to the study protocol and institutional practice. Stable anticoagulation may be permitted when appropriate periprocedural interruption or management is considered safe by the investigator.
    • Active infection involving the planned biopsy or ablation site or access pathway.
    • Any anatomical or clinical condition considered by the investigator to make percutaneous biopsy or combined Cryo-Thermal Ablation unsafe.

  3. Clinically Significant Cardiovascular or Systemic Disease

    • Uncontrolled hypertension.
    • Unstable angina, myocardial infarction within 3 months before enrollment, New York Heart Association (NYHA) class II or higher heart failure considered clinically significant by the investigator, or severe/uncontrolled arrhythmia.
    • Severe or uncontrolled hepatic, renal, metabolic, or other systemic disease that could interfere with study treatment or assessment.

  4. Immunotherapy-Related Contraindications

    • Active or suspected autoimmune disease requiring systemic treatment, except for conditions permitted by the protocol, such as vitiligo, type 1 diabetes mellitus, or adequately controlled autoimmune hypothyroidism.
    • History of autoimmune disease requiring systemic treatment with disease-modifying agents, corticosteroids, or immunosuppressive therapy within 2 years before enrollment, except as specifically permitted by the protocol.
    • Requirement for chronic systemic immunosuppressive treatment.
    • Systemic glucocorticoid treatment within 7 days before initiation of systemic study treatment, except physiologic replacement therapy equivalent to prednisone ≤10 mg/day.
    • Uncontrolled peripheral neuropathy of grade ≥2 or other condition that, in the investigator's judgment, would substantially increase the risk of study treatment.
    • Psychiatric, cognitive, or other conditions that would prevent adequate informed consent or compliance with study procedures.

  5. Active or Clinically Significant Infection

    • Active tuberculosis or inadequately controlled tuberculosis treated within 1 year before enrollment.
    • Human immunodeficiency virus (HIV) infection with clinically significant immunodeficiency or acquired immunodeficiency syndrome (AIDS), as defined by the study protocol.
    • Active hepatitis B infection with HBV DNA above the protocol-defined acceptable limit.
    • Active hepatitis C infection with detectable HCV RNA.
    • Other uncontrolled active infection requiring systemic therapy that, in the investigator's judgment, would interfere with study treatment.

  6. Pulmonary Conditions

    • Interstitial lung disease, interstitial pneumonia, pneumoconiosis, drug-induced pneumonitis, or other clinically significant diffuse pulmonary disease that may increase the risk of study treatment.
    • Severe impairment of pulmonary function incompatible with the planned ablation, systemic therapy, or subsequent surgical resection.
    • Clinically uncontrolled pleural or pericardial effusion. Participants whose effusion is adequately controlled and clinically stable after drainage may be eligible according to investigator assessment and the study protocol.

  7. Other Malignancies

    • Another malignancy diagnosed within 2 years before enrollment, except malignancies with a negligible risk of metastasis or death that have been adequately treated, such as basal cell or squamous cell carcinoma of the skin or carcinoma in situ treated with curative intent.

  8. Concurrent or Recent Treatments

    • Participation in another interventional clinical trial or receipt of another investigational drug or investigational device within 4 weeks before the first study intervention.
    • Receipt of anti-cancer traditional Chinese patent medicines or systemic immunomodulatory agents, including thymosin, interferons, or interleukins, within 2 weeks before initiation of study treatment.
    • Receipt of a live attenuated vaccine within 30 days before initiation of study treatment. Inactivated vaccines, including inactivated influenza vaccines, are permitted.

  9. Pregnancy, Lactation, and Transplantation

    • Pregnancy or breastfeeding.
    • Unwillingness to comply with protocol-specified contraceptive requirements.
    • Previous organ or bone marrow transplantation, or planned transplantation during the study period.

  10. Other Exclusion Criteria

    • Known severe hypersensitivity or contraindication to toripalimab, protocol-specified chemotherapy agents, their excipients, or materials used in the ablation procedure.
    • Any other medical, psychological, social, or logistical condition that, in the investigator's judgment, makes the participant unsuitable for study enrollment or could interfere with treatment safety, protocol compliance, or interpretation of study results.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Platinum-Based Doublet Chemotherapy

    Participants will receive CT-guided Cryo-Thermal Ablation followed by 3 planned cycles of toripalimab plus histology-appropriate platinum-based doublet chemotherapy administered every 3 weeks, followed by curative-intent surgical resection after preoperative reassessment.

    Procedure: Cryo-Thermal Ablation · Drug: Toripalimab · Drug: Platinum-based doublet chemotherapy

Interventions

  • ProcedureCryo-Thermal Ablation

    Cryo-Thermal Ablation is a CT-guided percutaneous local ablation procedure performed on the primary lung tumor before initiation of neoadjuvant systemic therapy. Under CT guidance, one or more ablation probes are placed percutaneously into the target lesion. Sequential cryogenic and thermal treatment is delivered according to the study protocol and device operating instructions. Technical parameters, including probe placement, treatment cycles, treatment duration, and target temperatures, will be standardized according to the protocol.

    Also known as: Ablation

  • DrugToripalimab

    Toripalimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, will be administered intravenously at a dose of 240 mg every 3 weeks (q3w) in combination with platinum-based doublet chemotherapy for 3 planned cycles following Cryo-Thermal Ablation. Dose interruption, delay, or discontinuation will be permitted when clinically indicated for treatment-related toxicity.

  • DrugPlatinum-based doublet chemotherapy

    Participants will receive protocol-specified platinum-based doublet chemotherapy in combination with toripalimab every 3 weeks for 3 planned cycles following Cryo-Thermal Ablation. The specific regimen will be selected according to tumor histology and the study protocol. Chemotherapy dosing, administration, dose modification, and supportive treatment will follow the protocol-defined regimen and standard clinical practice. After neoadjuvant therapy, disease reassessment will be performed before curative-intent surgical resection.

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR) Rate

    The proportion of enrolled participants who achieve pathological complete response (pCR), defined as no residual viable tumor cells in the resected primary tumor and all sampled regional lymph nodes after neoadjuvant treatment (ypT0N0). Participants who do not undergo surgical resection or for whom pathological response cannot be adequately assessed will not be considered to have achieved pCR in the primary efficacy analysis.

    Time frame: At pathological evaluation of the surgical resection specimen, with surgery planned approximately 4-6 weeks after the final neoadjuvant treatment.

Secondary outcomes

  1. Objective Response Rate (ORR)

    The proportion of enrolled participants who achieve a complete response (CR) or partial response (PR) as their radiographic tumor response before surgery, as assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: At preoperative radiographic reassessment, approximately 4-6 weeks after the final neoadjuvant treatment.

  2. Major Pathological Response (MPR) Rate

    The proportion of enrolled participants who achieve major pathological response (MPR), defined as ≤10% residual viable tumor cells within the primary tumor bed in the resected lung specimen after neoadjuvant treatment, based on pathological assessment according to IASLC recommendations. Pathological response in regional lymph nodes will be assessed and reported separately and will not be included in the primary definition of MPR.

    Time frame: At pathological evaluation of the surgical resection specimen, with surgery planned approximately 4-6 weeks after the final neoadjuvant treatment.

  3. R0 resection rate

    The proportion of participants undergoing surgical resection who achieve an R0 resection, defined as complete macroscopic resection of the tumor with microscopically negative surgical margins and no residual tumor at the resection margins.

    Time frame: At surgical and pathological evaluation of the resection specimen, with surgery planned approximately 4-6 weeks after the final neoadjuvant treatment.

  4. Event-Free Survival (EFS)

    Event-free survival (EFS) is defined as the time from enrollment to the first occurrence of any of the following events: radiographic disease progression; local disease progression resulting in unresectability; inability to undergo the planned curative-intent surgery because of treatment-related toxicity or deterioration in clinical condition attributable to study treatment; failure to achieve tumor resection because of intraoperative unresectability; local or distant disease recurrence after surgery; or death from any cause. Participants without an EFS event will be censored at the date of the last disease assessment.

    Time frame: From enrollment until the first EFS event, death, last disease assessment, or end of follow-up, up to approximately 5 years.

  5. Overall Survival (OS)

    Overall survival (OS) is defined as the time from enrollment to death from any cause. Participants who are alive at the time of analysis will be censored at the date they were last known to be alive.

    Time frame: From enrollment until death from any cause or the end of follow-up, up to approximately 5 years.

  6. Change From Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life Score

    Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). The Global Health Status/Quality of Life scale is transformed to a score ranging from 0 to 100, with higher scores indicating better overall health status and quality of life. Changes from baseline will be evaluated across predefined perioperative assessment time points.

    Time frame: Baseline before Cryo-Thermal Ablation; preoperative assessment approximately 4-6 weeks after the final neoadjuvant treatment; and approximately 30 days after surgical resection.

  7. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    The proportion of participants who experience one or more treatment-emergent adverse events (TEAEs). Adverse events will be assessed for type, severity, and relationship to study treatment and graded according to NCI-CTCAE version 5.0. Safety assessments will include events associated with Cryo-Thermal Ablation, neoadjuvant chemoimmunotherapy, and the perioperative treatment course.

    Time frame: From Cryo-Thermal Ablation through 30 days after surgical resection; for participants not undergoing surgery, through 30 days after discontinuation of protocol-defined treatment.

Other outcomes

  1. Changes in the Spatial Tumor Immune Microenvironment Assessed by Atera In Situ Spatial Transcriptomics

    Atera In Situ single-cell spatial transcriptomic profiling will be performed on FFPE tumor specimens. Within-participant changes from the baseline tumor biopsy before Cryo-Thermal Ablation to the surgical tumor specimen after neoadjuvant chemoimmunotherapy will be evaluated. Spatial immune features in the surgical specimen will also be compared among residual tumor, adjacent tissue, and normal lung tissue when available. Analyses will characterize spatial distributions and transcriptional states of CD8+ T cells, regulatory T cells, myeloid populations, interferon-related signaling, antigen-presentation pathways, and T-cell activation/exhaustion programs. Features will also be compared between participants with and without MPR; pCR will be explored as a subgroup.

    Time frame: Baseline tumor biopsy before Cryo-Thermal Ablation and surgical resection approximately 4-6 weeks after the final neoadjuvant treatment.

  2. Changes in Peripheral and Tumor T-cell Receptor Clonality Assessed by Bulk TCR Sequencing

    Bulk T-cell receptor sequencing (TCR-seq) will be performed on peripheral blood mononuclear cells and tumor tissue to characterize treatment-associated T-cell clonal dynamics. Peripheral blood will be collected at baseline before Cryo-Thermal Ablation, approximately 14 days after ablation before Cycle 1, before Cycles 2 and 3 of neoadjuvant chemoimmunotherapy, and after completion of neoadjuvant therapy before surgery. TCR repertoire diversity, clonality, and clonal expansion will be evaluated longitudinally. Tumor tissue from the baseline biopsy and surgical resection specimen will also undergo TCR-seq. Changes in intratumoral T-cell clonality and overlap between blood and tumor TCR clonotypes will be explored in relation to pathological response and treatment-related toxicity.

    Time frame: Peripheral blood: baseline; Day 14 after ablation before Cycle 1; before Cycle 2 (approximately Day 35) and Cycle 3 (approximately Day 56); and preoperative assessment 4-6 weeks after Cycle 3. Tumor tissue: baseline biopsy and surgical resection.

  3. Tumor Genomic Alterations Assessed by a 919-Gene Next-Generation Sequencing Panel

    Baseline FFPE tumor biopsy specimens will undergo next-generation sequencing using a 919-gene cancer-associated panel. Somatic genomic alterations, including relevant mutations and other detectable genomic features, will be characterized. Exploratory analyses will evaluate associations between baseline tumor genomic characteristics and pathological response to Cryo-Thermal Ablation combined with neoadjuvant chemoimmunotherapy.

    Time frame: Baseline tumor biopsy before Cryo-Thermal Ablation.

  4. Longitudinal Changes in Circulating Tumor DNA and Molecular Residual Disease

    Circulating tumor DNA (ctDNA) will be longitudinally assessed to characterize changes in tumor-derived molecular signals during treatment and postoperative surveillance. During neoadjuvant treatment, ctDNA levels and detectable tumor-associated alterations will be evaluated at baseline before ablation, 14 days after ablation, and at the preoperative assessment after completion of neoadjuvant therapy. ctDNA clearance and changes in variant allele abundance will be explored according to pathological response. Serial postoperative ctDNA testing will be used to assess molecular residual disease (MRD) and its relationship with subsequent disease recurrence. Longitudinal ctDNA profiles will also be explored for changes in detectable tumor clones over time.

    Time frame: Baseline before ablation; Day 14 after ablation; at the preoperative assessment approximately 4-6 weeks after the final neoadjuvant treatment; and Months 1, 4, 7, 10, 16, 22, 28, and 34 after surgery.

  5. Spatial Immune Phenotypes Assessed by Imaging Mass Cytometry

    Imaging Mass Cytometry (IMC) will be performed on selected FFPE surgical tumor specimens after neoadjuvant treatment as an orthogonal protein-level validation of spatial immune findings. Analyses will quantify selected immune cell populations and protein markers, including CD8+ T cells, regulatory T cells, myeloid populations, PD-L1, antigen-presentation markers, and markers of immune activation or proliferation such as granzyme B (GZMB) and Ki-67. Spatial relationships between immune cells and tumor cells, including immune-cell density, cellular proximity, and tumor-immune spatial organization, will be compared between participants with MPR and those without MPR. pCR cases will be explored as a subgroup where evaluable tissue is available.

    Time frame: At surgical resection, approximately 4-6 weeks after the final neoadjuvant treatment.

  6. Intratumoral Microbial Relative Abundance Assessed by Metagenomic Sequencing

    Tumor or tumor-bed specimens obtained at surgical resection will undergo metagenomic sequencing to characterize the intratumoral microbiome. The relative abundance of detected microbial taxa will be quantified and reported as the percentage of the total microbial abundance represented by each taxon. Microbial relative abundance profiles will be compared between participants with major pathological response (MPR) and those without MPR. Pathological complete response (pCR) cases will be explored as a subgroup when tumor-bed specimens are technically evaluable.

    Time frame: At surgical resection, approximately 4-6 weeks after the final neoadjuvant treatment.

  7. Intratumoral Metabolite Abundance Assessed by Metabolomic Profiling

    Tumor or tumor-bed specimens obtained at surgical resection will undergo metabolomic profiling to characterize intratumoral metabolic features. Detected metabolites will be quantified using normalized metabolite abundance, expressed as normalized signal intensity in arbitrary units. Metabolite abundance profiles will be compared between participants with major pathological response (MPR) and those without MPR. Pathological complete response (pCR) cases will be explored as a subgroup when tumor-bed specimens are technically evaluable.

    Time frame: At surgical resection, approximately 4-6 weeks after the final neoadjuvant treatment.

07

Study locations

1 of 9 sites recruiting
  • The Third People's Hospital of Chengdu
    Chengdu, Sichuan 610031, China
    Not yet recruiting
  • Sichuan Cancer Hospital & Institute
    Chengdu, Sichuan 610041, China
    Not yet recruiting
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
    Recruiting
  • Public Health Clinical Center of Chengdu
    Chengdu, Sichuan 610066, China
    Not yet recruiting
  • The Affiliated Hospital of Southwest Medical University
    Luzhou, Sichuan 646000, China
    Not yet recruiting
  • Meishan People's Hospital
    Meishan, Sichuan 620010, China
    Not yet recruiting
  • Affiliated Hospital of North Sichuan Medical College
    Nanchong, Sichuan 637000, China
    Not yet recruiting
  • Suining Central Hospital
    Suining, Sichuan 629000, China
    Not yet recruiting
  • Zigong Fourth People's Hospital
    Zigong, Sichuan 643000, China
    Not yet recruiting
08

References and documents

Publications

  • Mooradian MJ, Fintelmann FJ, LaSalle TJ, Simon J, Graur A, Muzikansky A, Mino-Kenudson M, Shalhout S, Kaufman HL, Jenkins RW, Lawrence D, Lawless A, Sharova T, Uppot RN, Fang J, Blaum EM, Gonye ALK, Gushterova I, Boland GM, Azzoli C, Hacohen N, Sade-Feldman M, Sullivan RJ. Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial. Nat Commun. 2024 Aug 27;15(1):7357. doi: 10.1038/s41467-024-51722-x. PubMed 39191779 ↗
  • Gu S, Luo Q, Zhang Y, Qian L, Chen K, Liang F, Hu Y, Zhou R, Wang Y, Liu J, Ning Z, Xu L, Meng Z, Li Y, Wang P. Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial. Nat Cancer. 2026 Jan;7(1):60-79. doi: 10.1038/s43018-025-01058-2. Epub 2025 Nov 1. PubMed 41176543 ↗
  • Lu S, Zhang W, Wu L, Wang W, Zhang P; Neotorch Investigators; Fang W, Xing W, Chen Q, Yang L, Mei J, Tan L, Sun X, Xu S, Hu X, Yu G, Yu D, Yang N, Chen Y, Shan J, Xing L, Tian H, Zhang X, Zhou M, Fang H, Wu G, Liu Y, Ye M, Cao L, Jiang J, Li X, Zhu L, Li S, Kang M, Zhong A, Chen K, Wu N, Sun Q, Ma H, Cai K, Wang C, Lin G, Zhu K, Zhang Y, Zhang X, Hu H, Zhang W, Chen J, Yang Z, Hang X, Hu J, Huang Y, Zhang Z, Zhang L, Zhang L, Liu L, Lin D, Zhang J, Chen G, Li Y, Zhu L, Wang W, Yu W, Cao D, Keegan P, Yao S. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. JAMA. 2024 Jan 16;331(3):201-211. doi: 10.1001/jama.2023.24735. PubMed 38227033 ↗
  • Liu Z, Yang Z, Wu J, Zhang W, Sun Y, Zhang C, Bai G, Yang L, Fan H, Chen Y, Zhang L, Jiang B, Liu X, Ma X, Tang W, Liu C, Qu Y, Yan L, Zhao D, Wu Y, He S, Xu L, Peng L, Chen X, Zhou B, Zhao L, Zhao Z, Tan F, Zhang W, Yi D, Li X, Gao Q, Zhang G, Wang Y, Yang M, Fu H, Guo Y, Hu X, Cai Q, Qi L, Bo Y, Peng H, Tian Z, She Y, Zou C, Zhu L, Cheng S, Zhang Y, Zhong W, Chen C, Gao S, Zhang Z. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell. 2025 May 29;188(11):3081-3096.e19. doi: 10.1016/j.cell.2025.03.018. Epub 2025 Mar 26. PubMed 40147443 ↗
  • Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023 Sep;20(9):624-639. doi: 10.1038/s41571-023-00798-3. Epub 2023 Jul 21. PubMed 37479810 ↗

Individual participant data

Plan to share: No — Individual participant data are not planned for public sharing because the study includes sensitive clinical, genomic, and multi-omics data. Data sharing may be considered in accordance with participant consent, ethics committee approval, institutional policies, and applicable data protection requirements.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855965
Lead sponsor
West China Hospital
Responsible party
Hu Liao (Deputy Director & Medical Team Leader, Department of Thoracic Surgery, West China Hospital, Sichuan University; Associate Professor of Surgery; Master's Supervisor, West China Hospital) — Principal investigator
First posted
Oct 2, 2026
Start date
Sep 10, 2026
Primary completion
Aug 5, 2028 (estimated)
Completion
Aug 5, 2033 (estimated)
Last update
Oct 2, 2026

Study contacts

Beinuo Wang, MD
Contact
wang_beinuo@163.com
+86-191-0807-4950

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Carcinoma→

Other studies from this sponsor

West China Hospital

Start the discussion